MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Survival

Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma

The European Respiratory Journal 2017 March 15 [Print 2017] [Link] de Perrot M, Dong Z, Bradbury P, Patsios D, Keshavjee S, Leighl NB, Hope A, Feld R, Cho J Abstract Tumour thickness was assessed to determine if this parameter could refine patients’ selection for multimodality therapy in malignant pleural mesothelioma.We reviewed 65 consecutive treatment-naïve malignant […]

Comments Off on Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma

Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years

The Annals of Thoracic Surgery 2017 March [Epub November 5] [Link] Friedberg JS, Simone CB 2nd, Culligan MJ, Barsky AR, Doucette A, McNulty S, Hahn SM, Alley E, Sterman DH, Glatstein E, Cengel KA Abstract BACKGROUND: The purpose of this study was to assess survival for patients with malignant pleural mesothelioma (MPM), epithelial subtype, utilizing […]

Comments Off on Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years

Life Expectancy in Pleural and Peritoneal Mesothelioma

Lung Cancer International [Epub 2017 January] [Link] Shavelle R, Vavra-Musser K, Lee J, Brooks J Abstract Background. Mesothelioma is a rare cancer with a historically dire prognosis. We sought to calculate life expectancies for patients with pleural or peritoneal mesothelioma, both at time of diagnosis and several years later, and to examine whether survival has […]

Comments Off on Life Expectancy in Pleural and Peritoneal Mesothelioma

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit

European Journal of Cancer 2017 February [Epub ahead of print] [Link] Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O’Brien ME, Yap TA. Abstract BACKGROUND: We have previously reported a prognostic score […]

Comments Off on Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Oncologist 2017 February 10 [Epub ahead of print] [Link] Wang X1, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Kishor Ganti A, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H Abstract PURPOSE: The aim of this study was to investigate whether progression-free survival (PFS) can be considered […]

Comments Off on Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

European Journal of Surgical Oncology 2017 Janury 29 [Epub ahead of print] [Link] Sugarbaker PH, Chang D Abstract PURPOSE: Malignant peritoneal mesothelioma (MPM) is a rare disease with about 300 new cases per year in the USA. Its natural history is described as local progression within the peritoneal space in the absence of liver metastases […]

Comments Off on Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis

Oncotarget 2017 January 18 [Epub ahead of print] [Link] Pei D1, Li Y, Liu X, Yan S, Guo X, Xu X, Guo X Abstract Fibulin-3 has emerged as a promising novel biomarker in conforming or monitoring malignant pleural mesothelioma (MPM). This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. […]

Comments Off on Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis

Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues

Journal of Molecular Diagnostics 2017 January [Epub 2016 Nov 15] [Link] De Rienzo A, Cook RW, Wilkinson J, Gustafson CE, Amin W, Johnson CE, Oelschlager KM, Maetzold DJ, Stone JF, Feldman MD, Becich MJ, Yeap BY, Richards WG, Bueno R Abstract A molecular test performed using fresh-frozen tissue was proposed for use in the prognosis […]

Comments Off on Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues

Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma

European Journal of of Radiology [2017 January] [Link] Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T Abstract PURPOSE: Efficient monitoring of tumor responsiveness to chemotherapy is essential to mitigate high mortality risks and cytotoxic effects of chemotherapeutics. However, there is no consensus on the most […]

Comments Off on Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma

New therapeutic strategies for malignant pleural mesothelioma

Biochemical Pharmacology 2017 January [Epub ahead of print] [Link] Bonelli MA, Fumarola C, La Monica S, Alfieri R Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesothelium, commonly associated to asbestos exposure. Therapeutic actions are limited due to the late stage at which most patients are diagnosed and the […]

Comments Off on New therapeutic strategies for malignant pleural mesothelioma